Market Overview

UPDATE: Raymond James Upgrades Amsurg Following Sheridan Health Acquisition

Related AMSG
Must Watch Stocks for December 5, 2016
Mid-Afternoon Market Update: Crude Oil Up 1%; Five Below Shares Rise On Earnings Beat

In a report issued Friday, Raymond James upgraded its rating of Amsurg (NASDAQ: AMSG) from Market Perform to Strong Buy with a target price of $60.

Analyst John W. Ransom has raised his estimates for Amsurg with its acquisition of Sheridan Health on Thursday. This merger should help boost organic and EPS growth, as well.

Ransom also raised his EPS estimate from $2.77 to $3.15 for 2015.

Amsurg will open Friday at $45.74.

Latest Ratings for AMSG

Nov 2016MizuhoDowngradesBuyNeutral
Nov 2016Wells FargoUpgradesMarket PerformOutperform
Sep 2016CitigroupInitiates Coverage onBuy

View More Analyst Ratings for AMSG
View the Latest Analyst Ratings

Posted-In: John W. RansomAnalyst Color News Upgrades Price Target Analyst Ratings


Related Articles (AMSG)

View Comments and Join the Discussion!